Chronic Obstructive Pulmonary Disease (COPD) is a preventable, treatable respiratory disease involving airflow obstruction in the lungs. It includes chronic bronchitis and emphysema and is the fourth leading cause of death in the US. The document discusses the pathophysiology of COPD, risk factors like smoking, and management approaches including oxygen therapy, medications, and surgical options. Management involves addressing risk factors, treating exacerbations, and improving quality of life through pulmonary rehabilitation.
What is emphysema?
Emphysema is a condition that forms part of chronic obstructive pulmonary disease (COPD) and involves the enlargement of the air sacs in the lung.
The alveoli at the end of the bronchioles of the lung become enlarged because of the breakdown of their walls. The fewer and larger damaged sacs that result mean there is a reduced surface area for the exchange of oxygen into the blood and carbon dioxide out of it.
Definition
Emphysema is a condition in which the alveoli become stiff expands and continuously filled the air even after expiration. Emphysema is a chronic obstructive disease due to lack of elasticity in the lungs and alveoli surface area.
Classification
Panlobular (panacinar)
It is damage to the respiratory bronchi, alveolar ducts and alveoli. All air space in the little lobes much enlarged, with little inflammatory disease. The characteristics that have chest hyperinflation, and is characterized by dyspnea on exertion, and weight loss.
CENTRILOBULAR (CENTROACINAR)
The pathological changes mainly occur in the centre of the secondary lobes, and peripheral of acini remain good. Often there is chaos-ventilation perfusion ratio, which lead to hypoxia, hypercapnia (increased CO2 in the arterial blood), polycythaemia and heart failure episodes right. The condition leads to cyanosis, peripheral oedema, and respiratory failure.
CAUSES OF EMPHYSEMA
The biggest known cause or risk factor for emphysema - and for COPD - is smoking. Cigarette smoking is responsible for around 90% of cases of COPD. However, COPD will develop only in smokers who are genetically susceptible - smoking does not always lead to the disease.
Thank you for selecting our 𝐂𝐎𝐏𝐃 PPT
This medical PowerPoint template about 𝐂𝐎𝐏𝐃
You can download our template by visiting our website:
https://www.rxslides.com/product/copd-powerpoint-template
copy and paste this URL into the browser and download the full editable template.
This 𝐂𝐎𝐏𝐃 animated template is designed by RxSlides, a medical professional team covering the following topics about 𝐂𝐎𝐏𝐃
𝐓𝐡𝐞 𝐭𝐞𝐦𝐩𝐥𝐚𝐭𝐞 𝐜𝐨𝐯𝐞𝐫𝐬 𝐭𝐡𝐞 𝐟𝐨𝐥𝐥𝐨𝐰𝐢𝐧𝐠 𝐭𝐨𝐩𝐢𝐜𝐬
𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧
Chronic obstructive pulmonary disease (𝐂𝐎𝐏𝐃) is a group of lung diseases that cause airflow blockage and breathing-related problems.
𝐩𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞
COPD is more prevalent in developing countries, but it is also a growing problem in developed countries. In the United States, COPD is the third leading cause of death.
Forms of 𝐂𝐎𝐏𝐃
• Chronic bronchitis
• Emphysema
𝐏𝐚𝐭𝐡𝐨𝐩𝐡𝐲𝐬𝐢𝐨𝐥𝐨𝐠𝐲
In normal lungs, air flows freely in and out of the bronchi and alveoli. However, in people with COPD, the airflow is blocked. This can be caused by inflammation of the airways, mucus production, or damage to the air sacs.
𝐑𝐢𝐬𝐤 𝐅𝐚𝐜𝐭𝐨𝐫𝐬
There are several risk factors for COPD, including smoking, air pollution, and genetics. Smoking is the most common risk factor for COPD. Smoking is responsible for about 80% of COPD cases. Air pollution, particularly indoor air pollution from cooking and burning fuels, can also increase the risk of COPD. Genetics can also play a role in COPD. People with a family history of COPD are more likely to develop the disease.
𝐜𝐚𝐮𝐬𝐞𝐬
The main causes of COPD are smoking and air pollution. Smoking damages the lungs and makes it difficult to breathe
𝐒𝐭𝐚𝐠𝐞𝐬
• Stage 1
• Stage 2
• Stage 3
.
𝐒𝐲𝐦𝐩𝐭𝐨𝐦𝐬
The most common symptoms of COPD are:
• Shortness of breath
• Cough
• Wheezing
• Chest tightness
• Fatigue
𝐂𝐨𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬
COPD can lead to several complications, including:
• Anemia
• Right-sided heart failure
• Muscle weakness
• Lung infections
• Bone thinning
• Collapsed lungs
𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐦𝐞𝐭𝐡𝐨𝐝𝐬
COPD is diagnosed with a spirometry test, which measures how much air a person can exhale.
𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐎𝐩𝐭𝐢𝐨𝐧𝐬
There is no cure for COPD, but there are treatments that can help manage the symptoms and slow the progression of the disease. Treatment options include:
• Bronchodilators
• Antibiotics
• Supplemental oxygen
• Vaccination
𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐯𝐞 𝐌𝐞𝐭𝐡𝐨𝐝𝐬
The best way to prevent COPD is to avoid smoking and air pollution. Several lifestyle changes can help reduce the risk of COPD, such as eating a healthy diet and exercising regularly.
Visit our site for more animated templates
𝗵𝘁𝘁𝗽𝘀://𝘄𝘄𝘄.𝗿𝘅𝘀𝗹𝗶𝗱𝗲𝘀.𝗰𝗼𝗺
RxSlides PowerPoint icons and illustrations related to 𝐂𝐎𝐏𝐃 will help you customize the content of this editable presentation according to your content and audience interest.
Chronic obstructive pulmonary disease..It is one of the most affecting lung disease.. In detailed explanation of disease is there and including its ayurvedic aspect of management is also there...
#Ayurveda#Emphysema#Chronic brochitis
This presentation is about Emphysema and Chronic Bronchitis made by CHAKRAPANI BHUVANESH.
Bronchitis is an inflammation of the lining of your bronchial tubes, which carry air to and from your lungs. People who have bronchitis often cough up thickened mucus, which can be discolored. Bronchitis may be either acute or chronic.
Chronic obstructive pulmonary disease (COPD)- Preeti sharmaEducate with smile
COPD is a type of obstructive lung disease and related conditions. it is very helpful presentation to you about information of COPD.
It includes all things that is definition, causes, symptoms, pathophysiology, diagnostic evaluation, types, treatment and role of nurses for COPD patient.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
What is emphysema?
Emphysema is a condition that forms part of chronic obstructive pulmonary disease (COPD) and involves the enlargement of the air sacs in the lung.
The alveoli at the end of the bronchioles of the lung become enlarged because of the breakdown of their walls. The fewer and larger damaged sacs that result mean there is a reduced surface area for the exchange of oxygen into the blood and carbon dioxide out of it.
Definition
Emphysema is a condition in which the alveoli become stiff expands and continuously filled the air even after expiration. Emphysema is a chronic obstructive disease due to lack of elasticity in the lungs and alveoli surface area.
Classification
Panlobular (panacinar)
It is damage to the respiratory bronchi, alveolar ducts and alveoli. All air space in the little lobes much enlarged, with little inflammatory disease. The characteristics that have chest hyperinflation, and is characterized by dyspnea on exertion, and weight loss.
CENTRILOBULAR (CENTROACINAR)
The pathological changes mainly occur in the centre of the secondary lobes, and peripheral of acini remain good. Often there is chaos-ventilation perfusion ratio, which lead to hypoxia, hypercapnia (increased CO2 in the arterial blood), polycythaemia and heart failure episodes right. The condition leads to cyanosis, peripheral oedema, and respiratory failure.
CAUSES OF EMPHYSEMA
The biggest known cause or risk factor for emphysema - and for COPD - is smoking. Cigarette smoking is responsible for around 90% of cases of COPD. However, COPD will develop only in smokers who are genetically susceptible - smoking does not always lead to the disease.
Thank you for selecting our 𝐂𝐎𝐏𝐃 PPT
This medical PowerPoint template about 𝐂𝐎𝐏𝐃
You can download our template by visiting our website:
https://www.rxslides.com/product/copd-powerpoint-template
copy and paste this URL into the browser and download the full editable template.
This 𝐂𝐎𝐏𝐃 animated template is designed by RxSlides, a medical professional team covering the following topics about 𝐂𝐎𝐏𝐃
𝐓𝐡𝐞 𝐭𝐞𝐦𝐩𝐥𝐚𝐭𝐞 𝐜𝐨𝐯𝐞𝐫𝐬 𝐭𝐡𝐞 𝐟𝐨𝐥𝐥𝐨𝐰𝐢𝐧𝐠 𝐭𝐨𝐩𝐢𝐜𝐬
𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧
Chronic obstructive pulmonary disease (𝐂𝐎𝐏𝐃) is a group of lung diseases that cause airflow blockage and breathing-related problems.
𝐩𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞
COPD is more prevalent in developing countries, but it is also a growing problem in developed countries. In the United States, COPD is the third leading cause of death.
Forms of 𝐂𝐎𝐏𝐃
• Chronic bronchitis
• Emphysema
𝐏𝐚𝐭𝐡𝐨𝐩𝐡𝐲𝐬𝐢𝐨𝐥𝐨𝐠𝐲
In normal lungs, air flows freely in and out of the bronchi and alveoli. However, in people with COPD, the airflow is blocked. This can be caused by inflammation of the airways, mucus production, or damage to the air sacs.
𝐑𝐢𝐬𝐤 𝐅𝐚𝐜𝐭𝐨𝐫𝐬
There are several risk factors for COPD, including smoking, air pollution, and genetics. Smoking is the most common risk factor for COPD. Smoking is responsible for about 80% of COPD cases. Air pollution, particularly indoor air pollution from cooking and burning fuels, can also increase the risk of COPD. Genetics can also play a role in COPD. People with a family history of COPD are more likely to develop the disease.
𝐜𝐚𝐮𝐬𝐞𝐬
The main causes of COPD are smoking and air pollution. Smoking damages the lungs and makes it difficult to breathe
𝐒𝐭𝐚𝐠𝐞𝐬
• Stage 1
• Stage 2
• Stage 3
.
𝐒𝐲𝐦𝐩𝐭𝐨𝐦𝐬
The most common symptoms of COPD are:
• Shortness of breath
• Cough
• Wheezing
• Chest tightness
• Fatigue
𝐂𝐨𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬
COPD can lead to several complications, including:
• Anemia
• Right-sided heart failure
• Muscle weakness
• Lung infections
• Bone thinning
• Collapsed lungs
𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐦𝐞𝐭𝐡𝐨𝐝𝐬
COPD is diagnosed with a spirometry test, which measures how much air a person can exhale.
𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐎𝐩𝐭𝐢𝐨𝐧𝐬
There is no cure for COPD, but there are treatments that can help manage the symptoms and slow the progression of the disease. Treatment options include:
• Bronchodilators
• Antibiotics
• Supplemental oxygen
• Vaccination
𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐯𝐞 𝐌𝐞𝐭𝐡𝐨𝐝𝐬
The best way to prevent COPD is to avoid smoking and air pollution. Several lifestyle changes can help reduce the risk of COPD, such as eating a healthy diet and exercising regularly.
Visit our site for more animated templates
𝗵𝘁𝘁𝗽𝘀://𝘄𝘄𝘄.𝗿𝘅𝘀𝗹𝗶𝗱𝗲𝘀.𝗰𝗼𝗺
RxSlides PowerPoint icons and illustrations related to 𝐂𝐎𝐏𝐃 will help you customize the content of this editable presentation according to your content and audience interest.
Chronic obstructive pulmonary disease..It is one of the most affecting lung disease.. In detailed explanation of disease is there and including its ayurvedic aspect of management is also there...
#Ayurveda#Emphysema#Chronic brochitis
This presentation is about Emphysema and Chronic Bronchitis made by CHAKRAPANI BHUVANESH.
Bronchitis is an inflammation of the lining of your bronchial tubes, which carry air to and from your lungs. People who have bronchitis often cough up thickened mucus, which can be discolored. Bronchitis may be either acute or chronic.
Chronic obstructive pulmonary disease (COPD)- Preeti sharmaEducate with smile
COPD is a type of obstructive lung disease and related conditions. it is very helpful presentation to you about information of COPD.
It includes all things that is definition, causes, symptoms, pathophysiology, diagnostic evaluation, types, treatment and role of nurses for COPD patient.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
2. Chronic Obstructive
Pulmonary Disease (COPD)
is a preventable treatable slowly progressive respiratory
disease of airflow obstruction involving the airways,
pulmonary parenchyma, or both.
COPD may include diseases that cause airflow obstruction
(e.g., emphysema, chronic bronchitis) or any combination
of these disorder. Other diseases such as cystic fibrosis
(CF), bronchiectasis, and asthma are classified as chronic
pulmonary disorders.
While COPD and lower respiratory diseases are the fourth
leading cause of death of people of all ages in the US,
they are the third leading cause of death for people ages
65 and over.
3. Pathophysiology
People with COPD commonly become symptomatic during the middle
adult years, and the incidence of the disease increases with age.
In COPD, the airflow limitation is both progressive and associated with
the lungs’ abnormal inflammatory response to noxious particles or gases.
The inflammatory response occurs throughout the proximal and peripheral
airways, lung parenchyma, and pulmonary vasculature
Because of the chronic inflammation and the body’s attempts to repair it,
changes and narrowing occur in the airways.
In the proximal airways, changes include increased number of goblet cells
and enlarged submucosal glands, both of which lead to hypersecretion of
mucus
In the peripheral airways, inflammation causes thickening of the airway
wall, peribronchial fibrosis, exudate in the airway, and overall airway
narrowing.
4. Pathophysiology
Overtime, this ongoing injury-and-repair process causes scar tissue
formation and narrowing of the airway lumen.
Finally, the chronic inflammatory process affects the pulmonary
vasculature and causes thickening of the lining of the vessel and
hypertrophy of smooth muscle, which may lead to pulmonary
hypertension.
Processes related to imbalances of substances in the lung may also
contribute to airflow limitation.
5.
6. Chronic Bronchitis
COPD
a disease of airways, is
defined as the
presence of cough and
sputum production for
at least 3 months in
each of 2 consecutive
years
Constant irritation
causes the mucus -
secreting and goblet
cells to increase in
number
Bronchial walls also
become thickened,
further narrowing the
bronchial lumen.
8. Emphysema
COPD
is a pathologic term that
describes an abnormal
distention of the
airspaces beyond the
terminal bronchioles
and destruction of the
walls of the alveoli
9. Two main types of Emphysema, based on the changes taking place in the lung:
(Both types may occur in the same patient)
Take place mainly in the
center of the secondary
lobule, preserving the
peripheral portions of the
acinus
This leads to central
cyanosis and respiratory
failure
The patient also develops
peripheral edema
Centrilobular
There is a destruction of the
respiratory bronchiole, alveolar
duct, and alveolus
All airspaces within the lobule
are essentially enlarged, but
there is little inflammatory
disease
A hyperinflated chest, marked
by dyspnea on exertion, and
weight loss typically occurs
Panlobular
11. Management of Patient with Chronic Pulmonary Disease
Risk Factors
Environmental exposures and host factors:
Exposure to tobacco smoke accounts for an estimated 80 - 90 %
of cases of chronic obstructive pulmonary disease
Secondhand smoke
Increased age
Occupational exposure - dust, chemicals
Indoor and outdoor air pollution
Genetic abnormalities, including a deficiency of Alpha1-
antitrypsin, an enzyme inhibitor that normally counteracts the
destruction of lung tissue by certain other enzymes
Other environmental risk factors for COPD:
Other types of tobacco (e.g., pipes, cigars) and marijuana
Prolonged and intense exposure to occupational dust and chemicals
Indoor and outdoor air pollution
12. Management of Patient with Chronic Pulmonary Disease
It is generally a progressive disease characterized by
three primary symptoms: Chronic Cough
Sputum Production
Dyspnea
1.
2.
3.
Weight Loss
Patients with COPD who have a primary emphysematous
component, chronic hyperinflation leads to the “barrel
chest” thorax configuration Retraction of the
superclavicular fossae occurs on inspiration, causing the
shoulders to heave upward
Metabolic disturbances and depression
Clinical manifestations
13. Management of Patient with Chronic Pulmonary Disease
assessment and diagnostic findings
Health History
Physical Assessment
Spirometry
Arterial Blood Gas
Chest X-ray
CT chest scan
Screening for alpha1-
antitrypsin
Pulmonary function test
( four grades depending on the severity)
14. Management of Patient with Chronic Pulmonary Disease
Respiratory insufficiency and failure and major life-threatening
complications of COPD
Acute Respiratory insufficiency and failure may necessitate
ventilatory support until other acute complications, such as
infection, can be treated
Other complications”: Pneumonia, Chronic Atelectasis,
Pneumothorax, and Pulmonary Arterial Hypertension
complications
15. Medical Management | RISK REDUCTION
Smoking cessation
is the single most
cost - effective
intervention to
reduce the risk of
developing COPD
and to stop its
progression
Medical management
Smoking cessation
can begin in a
variety of health
core settings
Risk Reduction
16. Medical Management | OXYGEN THERAPY
is the administration
of oxygen at a
concentration
greater than that
found in the
environmental
atmosphere
Oxygen Therapy
To provide
adequate transport
of oxygen in the
blood while
decreasing the
work of breathing
and reducing stress
on the mycocardium
17. Oxygen Therapy
A change in the patient’s
respiratory rate or pattern
may be one of the earliest
indicators of the need for
oxygen therapy
These changes may result
from hypoxemia or hypoxia
The need for oxygen is
assessed by arterial blood
gas analysis, pulse oximetry,
and clinical evaluation
indications complications
In terms of oxyhemoglobin
dissociation curve, arterial
hemoglobin at these levels
is 80% to 98% saturated
with oxygen
Oxygen toxicity may occur
when too high
concentration of oxygen is
given for an extended
period
Medical Management | OXYGEN THERAPY
18. Oxygen Therapy
Oxygen is dispensed from a
cylinder or a piped-in system
The use of oxygen concentrators
is another means of providing
varying amounts of oxygen,
especially in the home setting.
These devices are relatively
portable, easy to operate, and
cost - effectivebut require more
maintenance
Methodsof
oxygen
administration
Gerontologic
considerations
As the respiratory
muscles weaken and the
large bronchi and alveoli
become enlarged, the
available surface of the
lungs decreases,
resulting in reduced
ventilation and
respiratory gas
exchanged
Medical Management | OXYGEN THERAPY
19. Medical Management | OXYGEN THERAPY
Low-flowsystems
Different oxygen devices
Cannula
(nasal and reservoir)
(oropharyngeal) catheter
Nasal Mask, simple
20. Medical Management | OXYGEN THERAPY
Low-flowsystems
Different oxygen devices
Mask, partial
breathing
Mask, nonbreathing
21. Medical Management | OXYGEN THERAPY
high-flowsystems
Different oxygen devices
Mask, Venturi
Transtracheal oxygen
catheter
Mask, aerosol
22. Medical Management | OXYGEN THERAPY
high-flowsystems
Different oxygen devices
Trancheostomy collar
T - piece Face Tent
23. Medication regimens used to
manage COPD are based on
disease severity:
pharmacologic therapy
For Grade I (mild)
COPD, a short
acting
bronchodilator
may be prescribed
For Grade II or II
(moderate to severe)
COPD, a short acting
bronchodilator and
regular treatment with
one or more long-
acting bronchodilators
may be used
For Grade III or IV (severe
or very severe) COPD,
medication therapy includes
regular treatment with long-
acting bronchodilators
and/or inhaled
corticosteroids(ICSs) for
repeated exacerbations
Management of Patient with Chronic Pulmonary Disease
24. pharmacologic therapy
Bronchodilators
Long-acting bronchodilators
are more convenient for
patients to use
are typically used for
maintenance treatment for
long-term symptom
control
Short-acting bronchodilators
are usually used for acute
management of
symptomattic flairs
Pressurized metered-dose
inhalers (pMDIs)
contained aerosolized
powder of medications
Dry-powder inhalers (DPIs)
rely solely on the patient’s
inspiration for medication
deliveryy
Small-volume nebulizer (SVN)
handled with apparatus
that is easier to use than a
pMDI or a DPI but lacks the
convenience of these
inhalers as it requires a
power source in order to
operate
Management of Patient with Chronic Pulmonary Disease
26. Management of Patient with Chronic Pulmonary Disease
surgical management
BULLECTOMY
is a surgical option for select
patients with bullous
emphysema
it may help to reduce
dyspnea and improve lung
function
27. Management of Patient with Chronic Pulmonary Disease
surgical management
lungvolume
reductionsurgery
treatment options for patients with
advanced or end-stage COPD with a
primary emphysematous component
are limited, although lung volume
reduction surgery is a palliative
surgical option
28. Management of Patient with Chronic Pulmonary Disease
surgical management
LUNGTRANSPLANTATION
is a viable option for definitive
surgical treatment of severe
COPD in select patients
29. Management of Patient with Chronic Pulmonary Disease
surgical management
PULMONaryrehabilitaTION
one of the most cost-effective
treatment strategies, is a holistic
intervention aimed at improving
physical and psychological health of
patients with COPD